Furthermore, they proved that SESN2 is a clinically relevant target of p53 during colon carcinogenesis, and downregulation of SESN2 induces mTORC1 hyperactivation, which subsequently allowed for prominent tumour overgrowth (Ro et al. 2016). Here, SESN2 is linked to neoplasm.